The Journal for ImmunoTherapy of Cancer
is an open access journal that publishes high quality research, literature reviews, position papers and practice guidelines, and case studies on all components of cancer immunology and immunotherapy.
Impact Factor: 10.6
Citescore: 17.8
All metrics >>
Highlighted Articles
Authors
The Journal for ImmunoTherapy of Cancer accepts a variety of article types in a number of formats.
The Author Information section provides specific article requirements and section outlines to help you turn your research into an article suitable for JITC.
Information is also provided on editorial policy, Open Access fees and formatting.
Latest Articles
Immune cell therapies and immune cell engineering:
CD79A/CD40 intracellular domain uses a 4-1BB-like metabolic pathway driven by cholesterol biosynthesis11 March 2026
Basic and translational cancer immunology:
Dual regulation of CXCR6+CD8+ T cells modulates cytotoxic and exhaustion-associated programs during prostate cancer progression11 March 2026
Clinical cancer immunotherapy:
Evaluation of mixed response in tumor size and survival in patients with rare cancers treated with dual checkpoint inhibitor therapy (DART SWOG S1609)11 March 2026
Most Read Articles
Position article and guidelines:
Society for Immunotherapy of Cancer (SITC) consensus statement on essential biomarkers for immunotherapy clinical protocols7 March 2025
Position article and guidelines:
A SITC vision: adapting clinical trials to accelerate drug development in cancer immunotherapy22 March 2025
Immune cell therapies and immune cell engineering:
Potency-optimized CD28-activating bispecific antibody for the targeted treatment of Nectin-4 positive cancers5 April 2025
Immune cell therapies and immune cell engineering:
Adoptively transferred macrophages for cancer immunotherapy24 May 2025
Immune cell therapies and immune cell engineering:
IL-12-producing cytokine factories induce precursor exhausted T cells and elimination of primary and metastatic tumors1 April 2025
Altmetrics
Become a Reviewer for JITC
JITC offers many benefits to those who review for the journal, including discounts on Article Processing Charges (APC). Learn more about becoming a reviewer for JITC and volunteer for the role.
The journal also offers a Peer Review Mentorship Program for early career professionals with limited peer reviewing experience. A limited number of successful applicants are paired with senior leaders who help provide structural guidance on peer review to young researchers. Check the link below in summer for more information on key dates and how to apply to be a mentee in the next class.
About SITC
The Society for Immunotherapy of Cancer (SITC) is the world’s leading member-driven organization specifically dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy. As a way to thank the SITC members who work tirelessly to advance the science and improve the lives of cancer patients, SITC provides members with a 25% discount on Article Processing Charges (APCs) on papers where they serve as first, last, or corresponding author. This discount is applied post-acceptance, at which point a discount code is shared with the corresponding author.
For information on APC discounts and waivers – including those for members, editors or reviewers, low-income countries, or institutional arrangements – view the journal's APC policy.
Featured Video
Journal for the Immunotherapy of Cancer - our story
Meet Michael T Lotze, the Editor-in-chief for JITC, and hear what he has to say about the journal and its priorities.
Find out more